Xxxxx Xxxxxxx and Xx. XXX Xxxx as non-executive Directors; Dr. XX Xxx Xxx, Xx. XX Xxxxxxxx and Xx. XXXX Xxxx Xxxx as executive Directors and Xx. XXXX Wing Xxxx, Xxxxxx, Xx. XXXX Xxxxxxx, Xx. XXX Xxxxxxx and Mr. XX Xx as independent non-executive Directors.
Xxxxx Xxxxxxx and Xx. XXX Xxxx as non-executive Directors; Dr. XX Xxx Xxx, Xx. XX Xxxxxxxx and Xx. XXXX Xxxx Xxxx as executive Directors and Xx. XXXX Wing Xxxx, Xxxxxx, Xx. XXXX Xxxxxxx, Xx. XXX Xxxxxxx and Mr. XX Xx as independent non-executive Directors. If there is any inconsistency in this announcement between the Chinese and English versions, the English version shall prevail.
Xxxxx Xxxxxxx and Xx. Xxxx Xxxxxx (Mr. Xxxxx Xxx as his alternate) as non-executive Directors, and Xx. Xxxx Xxxx, Xx. Xxx Xxxxxx and Xx. Xxxx Xxxxx as independent non-executive Directors.
Xxxxx Xxxxxxx and Xx. Xxx Xxxxxxxx Xxxxxxx; and four independent non-executive directors of the Company, namely, Xx. Xxxxx Xxxx Xxx, Xx. Xx Xxxxxxxx, Xx. Xxx Xxxxxxxx and Xx. Xxxx Xxxx.
Xxxxx Xxxxxxx and Xx. Xxxx Xxxxx whilst the independent non-executive Directors of the Company are Xx. Xxxx Xxxxx Xxx, Xxxxx, Xx. Xx Xxx Xxx, Xx. Xxxx Jown Xxxx, Xxxxxxx and Xx. Xxxx Xxxxx-Xxxx.
Xxxxx Xxxxxxx and Xx. Xxxxx Xxxxx (above) enter a new partnership as Xxxxx launches a company around Xxxxxxx’s compounds. commercialization of compounds in the U.S. and abroad, Xxxxx had experience in all steps of the drug development process, from drug inception, preclinical and clinical development, to manufacturing and commercialization. He agreed to develop a business plan to license the patent portfolio of his former professor and to help find someone to execute it. Even though he’d worked for many startups, he wasn’t expecting to start his own company. He’d known Xxxxxxx for years—in fact, Xxxxxxx, then department chair of my long-standing relationship with Duquesne, I feel that I have a duty, an obligation to do good by this opportunity,” says Xxxxx. “Drug development is a long, bumpy road that requires a tremendous amount of patience, dedication and know-how. It could be up to 2 ½ years before FLAG can advance an investigational compound through the first phases of development. Ultimately, the goal is to get these compounds into the hands of people who can benefit from new treatment options.” The Bigger Picture Behind the Big Deal A deal with a company like FLAG, whose sole focus is Xxxxxxx’s compounds, offers the best opportunity for the compounds to enter the marketplace, says Xx. Xxxx X. Seadler, associate xxxxxxx for research and technology. Plus, the pervasive Duquesne thread woven between Xxxxxxx and Xxxxx provides a special connection. the pharmacy’s graduate school, presented Xxxxx with his master’s hood in 1990. Xxxxx certainly was aware of Xxxxxxx’s anti-cancer research. “But the more I learned about the work, the more intrigued I was,” says Xxxxx. “The small compounds were very intelligently designed and the strong patent portfolio around the work was incredibly impressive.” In June 2013, Xxxxx became founding president and CEO of FLAG Therapeutics Inc., creating a company around Xxxxxxx’s portfolio and making his relationship with Duquesne stronger than ever. Duquesne had provided Xxxxx’x academic foundation for three of his four degrees: pharmacy (’87, ’90) and an MBA in management (’90) from the School of Business, where son Xxxxx is a student. The pharmacy and MBA degrees were unusual combinations at the time, and Xxxxx discovered a love for the business of science. His Duquesne training, topped by a Ph.D. in pharmaceutical sciences from the University of Pittsburgh, set the stage for a varied career: as vice president of global science and technology at ...
Xxxxx Xxxxxxx and Xx. Xxx Xxxxxx for reading the finished manuscript and for their participation in the doctoral defense. I am also grateful for the many years of administrative assistance—and moral support—that I received from Xxxxxxx Xxxxxxxx, Xxxxxxxxx Xxxx, Xxxxxxx Xxxxxx, Xxxxxx Xxxxxx and Xxxxx Xxxxxx. This work is the result of many years spent studying the history of philosophy, an endeavor to which I would gladly devote myself many times over. Certain professors, at both Emory University and Loyola Marymount University, have been instrumental in this pursuit, and I would like to extend thanks to each of them for instilling in me the value of the historical approach to the discipline: Xx. Xxxxxx Xxxxxxx and the late Xxxxxx Xxxxxxx (Ancient); Xxxx Xxxx Xxxxxx, C.S.J and Xx. Xxxx Xxxxx (Medieval); Xx. Xxxxxx Xxxxxxxxxx, Xx. Xxxxxx Xxxxxx and Dr. Xxxxxxx Xxxxxx (Renaissance/Modern); and Xxxxxxx Xxxxxx (20th Century). Though writing a dissertation can be a solitary journey, I have been fortunate over the years to be surrounded by friends and family members who have supported me in this endeavor, both professionally and personally. Xxxxxxxxx Xxxxxx, Xxxxxx Xxxxxx xx Xxxxxxx and Xxxxxxxx Xxxxxx, in particular, offered much intellectual and moral support as I progressed towards a finished manuscript. They epitomize Cicero’s observation that “a true friend is, as it were, a second self,” and I am grateful for their companionship. Finally, I would like to thank my parents, Xxxxxxxxxxx and Xxxxx Xxxx, and my sister, Xxxxxxx Xxxx, for their assistance and encouragement, which has spanned almost two decades of studying philosophy. Their faith in my philosophical vocation has been unparalleled. I also thank my husband, Xxxxxxx Xxxxx, for his unconditional support in achieving this goal. He has surpassed all expectations that one might hope for in a spouse. Last, but certainly not least, I dedicate this work to my two daughters, my unknowing muses in all things—past, present and future. March 2016 CONTENTS
Xxxxx Xxxxxxx and Xx. Xxxxxxxxx Xxxxxx 4 OD • May 2021 Analysis Cover Article Xxxx Xxxxxxx DDS D ABDSM Sleep Apnea: Is Dentistry Doing Enough? S leep apnea affects almost one-billion people worldwide, leaving those afflicted feeling tired, accident prone, xxxxx, depressed and suscep- tible to a host of significant medical concerns, often culminating in a shortened lifespan (1). Particu- larly noteworthy during the COVID-19 pandemic is that unmanaged sleep apnea is associated with increased hos- pitalization from influenza infection (2). The alarming fact that more than 85 per cent of those afflicted with sleep apnea remain undiagnosed (1) begs the question: Is dentistry doing enough? What is sleep apnea and how is it managed? Sleep apnea involves disturbed breathing during sleep and is part of a spectrum of breathing issues, the most benign being simple snoring caused by soft tissue vibra- tion, followed by the narrowing of the airway leading to strained breathing, and finally to intermittent full collapse of the airway preventing breathing altogether. The gold standard therapy for sleep apnea is continuous positive airway pressure (CPAP), where a mask interface is used to splint the upper airway open through the use of pressurized air (3). Another conservative option is oral appliance therapy (OAT), which involves the use of an oral appliance to reposition the jaw and prevent it from dropping back during sleep, resulting in a more patent airway. It is not as effective as CPAP in eliminating all of the breathing events, but is much better tolerated by patients, and demonstrates a higher adherence rate than CPAP (4). How well is sleep apnea being managed? The American Academy of Sleep Medicine (AASM) doc- uments sleep apnea as a disease with remarkable medi- cal, social and economic impacts. A 22-country market research study conducted by SomnoMed, a leading oral-appliance manufacturer, documented approximately 2.5-million sleep studies performed during the 2020 fiscal year (estimated to be down by 0.5- million due to COVID-19). These studies resulted in approximately 1.9-million patients proceeding with therapy: 1.35- million with CPAP, 350,000 with OAT, and 200,000 with lifestyle changes, various surgery, etc. Of those trying CPAP, approximately 700,000 or 52 per cent dropped off. Of those trying OAT, approximately 28,000 or eight per cent dropped off. It is very notable that of the 700,000 patients who dropped off CPAP, most remained unmanaged. A Frost & Xxxxxxxx report commi...
Xxxxx Xxxxxxx and Xx. XXXX XXXXXXX Closed July 12, 1999. Medical Sale/Leaseback: Ophthalmologists CAP RATE: 10% 0000 Xxxxx Xxxxxx LEASE TERM: 5 YEARS Fort Xxxxx, Florida RENTAL RATE: $11 PSF NET Medical Building - 8,761 sq. ft. (1979) SALES PRICE: $110.00 PSF
